Team:UCL/Project

Circuit Overview

Our genetic circuit aims primarily to remove amyloid plaques in the brain, which are associated with Alzheimer’s disease, prevent neuroinflammation and support neurons.

Detection

Senile plaques increase the rate of production of reactive oxygen species that are damaging to brain cells. We developed an oxidative stress promoter, in order to initiate the production of other circuit parts.

Insertion

The brain is an immune privileged organ and the security of the blood brain barrier makes it difficult to get all but the smallest molecules, such as glucose, from the rest of the body into the brain. This makes inserting our genetic circuit into the brain a trickier task than in most synthetic biomedical projects. Here we examine some plausible methods.

Degradation

We expressed and characterised a matrix metalloproteinase that is capable of degrading amyloid. By increasing its expression in de-activated microglia, we hope to reduce amyloid burden in Alzheimer’s disease.

Selectable Marker

We used resistance to zeocin, a cell killing glycoprotein, to act as a selectable marker for transformation/transfection in our chassis; E.coli, HeLa and microglia.

Chassis

We conducted our experiments in three chassis, creating recombinant plasmids in E.coli before expressing them in HeLa and finally primary and immortalised human microglia lines.

Parts

We submitted X parts to the registry, LIST GENE NAMES and improved X, LIST GENE NAMES. To be filled in later

Future Developments

Our circuit design is far from finished; given sufficient time in the lab, we would have included several other important components, including the de-activating agent VIP and the support factor BDNF.

Experiments

Insert text.

Lab Protocols

Fill in later.

Safety

It is essential that both personnel and experimental products are as safe as possible to avoid harm. Risk may be minimised by following safety procedures for any plausible dangerous situation that may occur in the laboratory.